Pharmaceutical - Actelion

Filter

Current filters:

Actelion

Popular Filters

Actelion says PAH drug Opsumit now available in USA

Actelion says PAH drug Opsumit now available in USA

05-11-2013

Actelion has confirmed that Opsumit 10mg, an oral, dual endothelin receptor antagonist for pulmonary…

ActelionMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonary

Positive EMA/CHMP opinions for Actelion and Lundbeck

Positive EMA/CHMP opinions for Actelion and Lundbeck

27-10-2013

At its October month-end meeting, the European Medicines Agency’s Committee for Medicinal Products…

ActelionBiotechnologyBrintellixEuropeLundbeckNeurologicalOpsumitPharmaceuticalRegulationRespiratory and Pulmonary

Actelion to start Phase III studies into cadazolid for C. difficile related diarrhea

11-09-2013

Swiss biotech firm Actelion (SIX: ATLN) will initiate a Phase III clinical development program to assess…

ActelionAntibiotics and Infectious diseasescadazolidEuropePharmaceuticalResearchVancomycin

Actelion's Opsumit for PAH shows reduction in morbidity and mortality

10-09-2013

Swiss biotech firm Actelion (SIX: ATLN) has announced key morbidity and mortality data in pulmonary arterial…

ActelionOpsumitPharmaceuticalResearch

FDA staffers back riociguat approval, but with modified dose

05-08-2013

On Tuesday (August 6), the US Food and Drug Administration's Renal Drugs Advisory Committee will discuss…

ActelionAdempasBayerNorth AmericaOpsumitPharmaceuticalRegulationRespiratory and PulmonaryriociguatTracleer

US pulmonologists views on PAH prescribing options

19-07-2013

US pulmonologists surveyed by health care advisory firm Decision Resources consider a drug's effect on…

ActelionBayerMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonaryriociguat

New Zealand updates on Tracleer and sildenafil listing

21-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

ActelionArrow PharmaceuticalsAsia-PacificPharmaceuticalPricingRegulationRespiratory and PulmonarysildenafilTracleer

Actelion announces cost saving initiative; Ipsen to hang on to Dreux

12-07-2012

Europe largest biotech firm, Actelion (SIX: ATLN) this morning said it has launched a cost saving initiative…

ActelionBiotechnologyEuropeFinancialIpsenPharmaceutical

Auxilium and Actelion partner on Xiaflex

24-02-2012

biotech firm, have entered into a long-term partnership for the development, supply and commercialization…

ActelionAuxilium PharmaceuticalsBiotechnologyLicensingPharmaceuticalRare diseasesXiaflex

Clazosentan for traumatic brain injury shows promise in animals

20-02-2012

A new drug is showing promise in shielding against the harmful effects of traumatic brain injury (TBI)…

ActelionBiotechnologyclazosentanNeurologicalPharmaceuticalResearch

Actelion pulls out of Trophos option

13-12-2011

Switzerland-based Actelion (SIX: ATLN), Europe’s biggest biotech company, says that it has decided…

ActelionBiotechnologyLicensingMergers & AcquisitionsolesoximePharmaceuticalRare diseasesTrophos

Executive appointments at Merck & Co, Actelion and Jazz Pharma

28-09-2011

US drug giant Merck & Co (NYSE: MRK) has appointed Cuong Viet Do as chief strategy officer, effective…

ActelionBiotechnologyJazz PharmaceuticalsManagementMerck & CoPharmaceutical

Novartis cancer drug imatinib shows efficacy in PAH

26-09-2011

Swiss drug major Novartis (NOVN: VX) yesterday announced new data today at the European Respiratory Society…

ActelionCardio-vascularImatinib MesylateNovartisPharmaceuticalResearchRespiratory and PulmonaryTracleer

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top